FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Oliver Zolk

Research Profile

Living Beings

Anatomy

Chemicals & Drugs

Disorders

Physiology

Signal Transduction

Co-author Network

Publications

TOP 3
Rebecca Schnepf; Oliver Zolk
Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.
Oliver Zolk; Martin F Fromm; Heinrich Iro; Marc Muschler; Rebecca Schnepf; Maximilian Traxdorf; Olaf Wendler; Johannes Zenk
Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
D Trenk; Oliver Zolk; M F Fromm; F-J Neumann; Willibald Hochholzer
Personalizing antiplatelet therapy with clopidogrel.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Oliver Zolk (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Rebecca Schnepf; Oliver Zolk
Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.
Expert opinion on drug metabolism & toxicology 2013;9(3):287-306.
2013: Oliver Zolk; Martin F Fromm; Heinrich Iro; Marc Muschler; Rebecca Schnepf; Maximilian Traxdorf; Olaf Wendler; Johannes Zenk
Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
The American journal of pathology 2013;182(1):234-43.
2012: D Trenk; Oliver Zolk; M F Fromm; F-J Neumann; Willibald Hochholzer
Personalizing antiplatelet therapy with clopidogrel.
Clinical pharmacology and therapeutics 2012;92(4):476-85.
2012: Oliver Zolk; Martin F Fromm; Christian Ott; Roland E Schmieder
Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians.
Journal of clinical hypertension (Greenwich, Conn.) 2012;14(5):293-8.
2012: Oliver Zolk
Disposition of metformin: variability due to polymorphisms of organic cation transporters.
Annals of medicine 2012;44(2):119-29.
2012: Oliver Zolk; Martin F Fromm
Drug transporter regulation in tumors by DNA methylation.
Genome medicine 2012;4(1):10.
2011: Thomas F Solbach; Martin F Fromm; Markus Grube; Oliver Zolk
Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization.
Journal of cardiovascular pharmacology 2011;58(4):409-17.
2011: Dietmar Trenk; Christian M Valina; Oliver Zolk; Martin F Fromm; Willibald Hochholzer; Christian Stratz; Franz-Josef Neumann
Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
Circulation. Cardiovascular genetics 2011;4(4):429-36.
2011: Fabian Müller; Ingrid Schmidt; Oliver Zolk; Martin F Fromm; Hartmut Glaeser; Jörg König; Renke Maas
Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.
Antimicrobial agents and chemotherapy 2011;55(7):3091-8.
2011: Oliver Zolk; Martin F Fromm
Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.
Clinical pharmacology and therapeutics 2011;89(6):798-805.
2011: Jörg König; Oliver Zolk; K Singer; C Hoffmann; M F Fromm
Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations.
British journal of pharmacology 2011;163(3):546-55.
2010: Maren Poguntke; Eszter Hazai; Martin F Fromm; Oliver Zolk
Drug transport by breast cancer resistance protein.
Expert opinion on drug metabolism & toxicology 2010;6(11):1363-84.
2010: Ryan M Franke; Ashley M Kosloske; Cynthia S Lancaster; Kelly K Filipski; Chaoxin Hu; Oliver Zolk; Ron H J Mathijssen; Alex Sparreboom
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(16):4198-206.
2010: Michaela E Kraft; Hartmut Glaeser; Kathrin Mandery; Jörg König; Daniel Auge; Martin F Fromm; Ursula Schlötzer-Schrehardt; Ulrich Welge-Lüssen; Friedrich E Kruse; Oliver Zolk
The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost.
Investigative ophthalmology & visual science 2010;51(5):2504-11.
2010: Ulrike Werner; Dierk Werner; Svetlana Heinbüchner; Bernhard Graf; Hüseyin Ince; Stefan Kische; Petra Thürmann; Jörg König; Martin F Fromm; Oliver Zolk
Gender is an important determinant of the disposition of the loop diuretic torasemide.
Journal of clinical pharmacology 2010;50(2):160-8.
2009: S Klein; Oliver Zolk; Martin F Fromm; Falk Schrödl; Winfried Neuhuber; C Kryschi
Functionalized silicon quantum dots tailored for targeted siRNA delivery.
Biochemical and biophysical research communications 2009;387(1):164-8.
2009: Oliver Zolk; Thomas F Solbach; Jörg König; Martin F Fromm
Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(6):1312-8.
2009: Oliver Zolk; Thomas F Solbach; Jörg König; Martin F Fromm
Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).
Naunyn-Schmiedeberg's archives of pharmacology 2009;379(4):337-48.
2008: Oliver Zolk; Thomas F Solbach; Thomas Eschenhagen; Alexander Weidemann; Martin F Fromm
Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure.
Biochemical and biophysical research communications 2008;376(2):315-20.
2008: Rasti Krajcik; Adrian Jung; Andreas Hirsch; Winfried Neuhuber; Oliver Zolk
Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes.
Biochemical and biophysical research communications 2008;369(2):595-602.
2008: Thomas F Solbach; Barbara Paulus; Michael Weyand; Thomas Eschenhagen; Oliver Zolk; Martin F Fromm
ATP-binding cassette transporters in human heart failure.
Naunyn-Schmiedeberg's archives of pharmacology 2008;377(3):231-43.
2008: Dierk Werner; Ulrike Werner; Annett Meybaum; Boris Schmidt; Sumaira Umbreen; Anton Grosch; Heiko G Lestin; Bernhard Graf; Oliver Zolk; Martin F Fromm
Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
Clinical pharmacokinetics 2008;47(5):323-32.
2007: Burkhard Hinz; Olga Cheremina; Jouri Bachmakov; Bertold Renner; Oliver Zolk; Martin F Fromm; Kay Brune
Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(10):2343-51.
2007: Daniela Doll; Antonio Sarikas; Rasti Krajcik; Oliver Zolk
Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition.
Biochemical and biophysical research communications 2007;353(2):436-42.
2007: Oliver Zolk; Johannes Jacobi; Andreas Pahl; Martin F Fromm; Roland E Schmieder
MDR1 genotype-dependent regulation of the aldosterone system in humans.
Pharmacogenetics and genomics 2007;17(2):137-44.
2006: Oliver Zolk; Carolus Schenke; Antonio Sarikas
The ubiquitin-proteasome system: focus on the heart.
Cardiovascular research 2006;70(3):410-21.
2006: Ulrike Mühlhäuser; Oliver Zolk; Thomas Rau; Felix Münzel; Thomas Wieland; Thomas Eschenhagen
Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(6):785-7.
2006: Joachim Weil; Oliver Zolk; Jens Griepentrog; Ullrich Wenzel; Wolfram-Hubertus Zimmermann; Thomas Eschenhagen
Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction.
Cardiovascular research 2006;69(2):412-22.
2006: Thomas F Solbach; Jörg König; Martin F Fromm; Oliver Zolk
ATP-binding cassette transporters in the heart.
Trends in cardiovascular medicine 2006;16(1):7-15.
2005: Felix Münzel; Ulrike Mühlhäuser; Wolfram-Hubertus Zimmermann; Michael Didié; Karin Schneiderbanger; Peter Schubert; Sven Engmann; Thomas Eschenhagen; Oliver Zolk
Endothelin-1 and isoprenaline co-stimulation causes contractile failure which is partially reversed by MEK inhibition.
Cardiovascular research 2005;68(3):464-74.
2005: Liliana Castro; Jeanne Mialet Perez; Aurélie Guillemeau; Francesca Stillitano; Oliver Zolk; Thomas Eschenhagen; Frank Lezoualc'h; Pascal Bochet; Rodolphe Fischmeister
Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes.
Journal of molecular and cellular cardiology 2005;39(2):335-44.
2005: Oliver Zolk; Sven Engmann; Felix Münzel; Rasti Krajcik
Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue.
American journal of physiology. Endocrinology and metabolism 2005;288(6):E1214-21.
2005: Antonio Sarikas; Lucie Carrier; Carolus Schenke; Daniela Doll; Jeanne Flavigny; Katrin S Lindenberg; Thomas Eschenhagen; Oliver Zolk
Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.
Cardiovascular research 2005;66(1):33-44.
2004: Oliver Zolk; Felix Münzel; Thomas Eschenhagen
Effects of chronic endothelin-1 stimulation on cardiac myocyte contractile function.
American journal of physiology. Heart and circulatory physiology 2004;286(4):H1248-57.
2004: Ali El-Armouche; Torsten Pamminger; Diana Ditz; Oliver Zolk; Thomas Eschenhagen
Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts.
Cardiovascular research 2004;61(1):87-93.
2003: Ali El-Armouche; Oliver Zolk; Thomas Rau; Thomas Eschenhagen
Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure.
Cardiovascular research 2003;60(3):478-87.
2003: Ali El-Armouche; Oliver Zolk; Thomas Eschenhagen
[Citalopram].
Deutsche medizinische Wochenschrift (1946) 2003;128(43):2253-6.
2003: Oliver Zolk; Michael Marx; Elmar Jäckel; Ali El-Armouche; Thomas Eschenhagen
Beta-adrenergic stimulation induces cardiac ankyrin repeat protein expression: involvement of protein kinase A and calmodulin-dependent kinase.
Cardiovascular research 2003;59(3):563-72.
2003: Oliver Zolk; Norbert Thürauf
[Risperidone].
Deutsche medizinische Wochenschrift (1946) 2003;128(24):1353-6.
2003: Ute Seeland; Ichiro Kouchi; Oliver Zolk; Friedrich Jockenhövel; Gabi Itter; Wolfgang Linz; Michael Böhm
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.
European journal of heart failure 2003;5(3):241-6.
2003: Ali El-Armouche; Thomas Rau; Oliver Zolk; Diana Ditz; Torsten Pamminger; Wolfram-Hubertus Zimmermann; Elmar Jäckel; Sian E Harding; Peter Boknik; Joachim Neumann; Thomas Eschenhagen
Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(3):437-9.
2002: Oliver Zolk; Leong L Ng; Russell J O'Brien; Michael Weyand; Thomas Eschenhagen
Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance.
Circulation 2002;106(12):1442-6.
2002: Oliver Zolk; Marcus Frohme; Alexander Maurer; Franz-Werner Kluxen; Bernd Hentsch; Dimitri Zubakov; Jörg D Hoheisel; Irving H Zucker; Salvatore Pepe; Thomas Eschenhagen
Cardiac ankyrin repeat protein, a negative regulator of cardiac gene expression, is augmented in human heart failure.
Biochemical and biophysical research communications 2002;293(5):1377-82.
2002: Ute Seeland; Ichiro Kouchi; Oliver Zolk; Gabi Itter; Wolfgang Linz; Michael Böhm
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.
Journal of molecular and cellular cardiology 2002;34(2):151-63.
2002: Oliver Zolk; Jessika Quattek; Ute Seeland; Ali El-Armouche; Thomas Eschenhagen; Michael Böhm
Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats.
Cardiovascular research 2002;53(2):363-71.
2001: Oliver Zolk; Ali El-Armouche; Thomas Eschenhagen
[Drug interactions in the practice. Which combinations are taboo?].
MMW Fortschritte der Medizin 2001;143(51-52):24-32.
2001: Felix Münzel; Thomas Eschenhagen; Thomas Rau; Oliver Zolk
[Emergencies in the practice. Hazards of "mix syringe"].
MMW Fortschritte der Medizin 2001;143(44):44-7.
2001: Markus Flesch; S Ettelbrück; Stephan Rosenkranz; Christoph Maack; Bodo Cremers; K D Schlüter; Oliver Zolk; Michael Böhm
Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes.
Cardiovascular research 2001;49(2):371-80.
2000: Ichiro Kouchi; Oliver Zolk; Friedrich Jockenhövel; Gabi Itter; Wolfgang Linz; Bodo Cremers; Michael Böhm
Increase in G(i alpha) protein accompanies progression of post-infarction remodeling in hypertensive cardiomyopathy.
Hypertension 2000;36(1):42-7.
2000: Oliver Zolk; P Caroni; Michael Böhm
Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure.
Circulation 2000;101(23):2674-7.
2000: Oliver Zolk; Ichiro Kouchi; P Schnabel; Michael Böhm
Heterotrimeric G proteins in heart disease.
Canadian journal of physiology and pharmacology 2000;78(3):187-98.
1999: Kerstin Strehlow; Georg Nickenig; J Roeling; Sven Wassmann; Oliver Zolk; Andreas Knorr; Michael Böhm
AT(1) receptor regulation in salt-sensitive hypertension.
The American journal of physiology 1999;277(5 Pt 2):H1701-7.
1999: Oliver Zolk; J Quattek; G Sitzler; T Schrader; Georg Nickenig; Petra Schnabel; K Shimada; M Takahashi; Michael Böhm
Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure.
Circulation 1999;99(16):2118-23.
1999: Petra Schnabel; F Mies; Christoph Maack; Stephan Rosenkranz; Oliver Zolk; Michael Böhm
Beneficial effects of amiodarone in heart failure: interaction with beta-adrenoceptors rather than G proteins.
European journal of pharmacology 1999;369(3):391-4.
1998: Michael Böhm; M Castellano; Markus Flesch; Christoph Maack; M Moll; Martin Paul; F Schiffer; Oliver Zolk
Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy.
Hypertension 1998;32(5):831-7.
1998: Michael Böhm; S Ettelbrück; Markus Flesch; Wiek H van Gilst; Andreas Knorr; Christoph Maack; Yigal M Pinto; Martin Paul; AC Teisman; Oliver Zolk
Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy.
Cardiovascular research 1998;40(1):146-55.
1998: Oliver Zolk; Heiko Kilter; Markus Flesch; Pascale Mansier; Bernard Swynghedauw; Petra Schnabel; Michael Böhm
Functional coupling of overexpressed beta 1-adrenoceptors in the myocardium of transgenic mice.
Biochemical and biophysical research communications 1998;248(3):801-5.
1998: Oliver Zolk; Markus Flesch; Georg Nickenig; P Schnabel; Michael Böhm
Alteration of intracellular Ca2(+)-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats.
Cardiovascular research 1998;39(1):242-56.
1998: Georg Nickenig; Kerstin Strehlow; J Roeling; Oliver Zolk; Andreas Knorr; Michael Böhm
Salt induces vascular AT1 receptor overexpression in vitro and in vivo.
Hypertension 1998;31(6):1272-7.
1998: G Sitzler; Oliver Zolk; Ulrich Laufs; Martin Paul; Michael Böhm
Vascular beta-adrenergic receptor adenylyl cyclase system from renin-transgenic hypertensive rats.
Hypertension 1998;31(5):1157-65.
1998: Michael Böhm; Oliver Zolk; Markus Flesch; F Schiffer; Petra Schnabel; Johannes-Peter Stasch; Andreas Knorr
Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac beta-adrenergic signal transduction.
Hypertension 1998;31(3):747-54.
1998: Oliver Zolk; Markus Flesch; Petra Schnabel; AC Teisman; Yigal M Pinto; Wiek H van Gilst; Martin Paul; Michael Böhm
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
British journal of pharmacology 1998;123(3):405-12.
1997: Markus Flesch; F Schiffer; Oliver Zolk; Yigal M Pinto; Johannes-Peter Stasch; Andreas Knorr; S Ettelbrück; Michael Böhm
Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy.
Journal of hypertension 1997;15(9):1001-9.
1997: Markus Flesch; F Schiffer; Oliver Zolk; Yigal M Pinto; S Rosenkranz; C Hirth-Dietrich; G Arnold; Martin Paul; Michael Böhm
Contractile systolic and diastolic dysfunction in renin-induced hypertensive cardiomyopathy.
Hypertension 1997;30(3 Pt 1):383-91.
1997: Georg Nickenig; Oliver Jung; Kerstin Strehlow; Oliver Zolk; Wolfgang Linz; BA Schölkens; Michael Böhm
Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression.
The American journal of physiology 1997;272(6 Pt 2):H2701-7.